NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Hemanext

Hemanext

Private
Lexington, MassachusettsHealthcare & Life Scienceshttps://hemanext.com/

Last Round

Grant

Oct 14, 2025

Est. Valuation

$172M

Total Funding Raised

$100.8M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Hemanext is a medical technology company that develops oxygen-controlled processing and storage systems to preserve the quality and function of red blood cells for transfusion.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotech Equipment

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting

AI Layer

Non-AI

Keywords

blood storagered blood cell processingblood bankingmedical devicetransfusion medicinestorage lesion mitigationhypoxic blood storageblood supply chainblood bag technologyRBCblood processing disposablesblood center equipmentcold chain logistics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Hemanext Comps

Public and private peers based on sector, stage, and business model.

Hemanext comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Hemanext Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantOct 14, 2025
Series B ExtensionJul 22, 2025
Series B ExtensionJan 27, 2025
Series B ExtensionOct 1, 2024
StrategicJun 7, 2023
Series B
Nov 7, 2022

Key People

Founding team and executive leadership

Andrew Dunham

Chief Executive Officer, Chief Technology Officer

Executive Team

M. Shane Ray

President and Chief Executive Officer

Executive Team

Hemanext Investors

Notable investors and investment history

Hemanext investors
InvestorRounds
NIH RADxGrant
National Heart, Lung, and Blood InstituteGrant
Antaeus Enterprises, Inc.Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Oct 14, 2025

    $3M grant from the National Heart, Lung, and Blood Institute.

  • Jun 12, 2025

    Data presented at the European Hematology Association 2025 Congress.

Hemanext Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Hemanext Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Hemanext's valuation, stock price, and market status.

Firmographic Details

HeadquartersLexington, Massachusetts
Employee Range36
Year Founded2006
Last FundingOct 14, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.